THOUGHT OF THE DAY
Oil risk premium collapses on U.S.–Iran thaw
Crude fell roughly 12% in a week, its steepest weekly decline since early 2020, as diplomatic de-escalation with Iran met recovering Middle Eastern supply. The move marks an acceleration of the decline already underway: improved supply now reinforces the unwind of geopolitical risk premium. Natural gas did not move in lockstep; cooler weather supported a modest weekly gain in gas futures.
Signal: Favor a bearish crude stance through USO.US(United States Oil Fund), but treat UNG.US(United States Natural Gas Fund) as a separate weather-and-gas-market trade.
Pelacarsen failure rattles the Lp(a) drug thesis
Novartis halted pelacarsen after its Phase 3 trial failed to reduce cardiovascular events despite lowering Lp(a). That result challenges the assumption that lowering the biomarker will translate into fewer heart attacks and strokes, putting competing programs—including Amgen’s olpasiran—and related royalty exposure under scrutiny.
Signal: Reassess Lp(a)-linked pipeline and royalty valuations; the next critical test is whether olpasiran can show cardiovascular benefit, not just biomarker reduction.
MACRO SUMMARY
Today's Read: Corporate news points to strong but uneven growth. AI infrastructure demand remains tangible: AMD(Advanced Micro Devices) reported 97% growth in data-center revenue and guided to roughly $17 billion in Q4 revenue, while AAOI(Applied Optoelectronics) secured a hyperscaler agreement for 1.6T transceivers worth an estimated $1–1.5 billion through 2029. Yet demand does not guarantee attractive returns. CoreWeave’s debt burden, bond yields above 17%, and exposure to permitting delays show how financing costs and political constraints can disrupt the buildout.
Consumer signals also diverge by category. ABNB(Airbnb) and BKNG(Booking Holdings) reported strong travel demand and pricing, while weakness at Wynn and pressure on IFF’s supplement-related sales point to softness in parts of discretionary spending. Cost pressure remains visible: IFF expects an unfavorable price-cost gap into Q4, and labor, energy, and logistics costs continue to weigh on several companies. The oil selloff could ease some energy-cost pressure, but today’s corporate reports do not yet show broad relief.
Forward Catalysts
- CEG(Constellation Energy), NRG(NRG Energy), and OXY(Occidental Petroleum) report earnings next week, according to the summaries.
- NVDA(NVIDIA) reports Q3 earnings on November 17; investors will watch for signs that AI demand and margins can sustain current expectations.
- BEP(Brookfield Renewable Partners) faces a November 25 deadline for the vote on its BEPC simplification proposal.
ACTIONABLE IDEAS
Actionable Ideas (Positive)
- AMD(Advanced Micro Devices): Data-center revenue rose 97% year over year to $8.55 billion, and management guided to approximately $17 billion in Q4 revenue. The results support exposure to AI compute demand, while supply constraints remain the key execution risk.
- AAOI(Applied Optoelectronics): A Tier 1 hyperscaler signed a multi-year 1.6T transceiver agreement projected to generate $1–1.5 billion through 2029. The contract materially improves demand visibility; position for execution only with the capacity and DSP bottlenecks in view.
Actionable Ideas (Negative)
- USO.US(United States Oil Fund): Crude’s roughly 12% weekly decline reflects both easing U.S.–Iran tensions and recovering supply. Maintain bearish crude exposure while the geopolitical premium continues to unwind; watch for renewed supply disruption or a reversal in diplomacy.
- IONS(Ionis Pharmaceuticals): Novartis discontinued pelacarsen after the Phase 3 trial failed to reduce cardiovascular events, undermining confidence in the Lp(a) approach. Reduce exposure until competing clinical evidence supports a clear link between Lp(a) lowering and fewer cardiovascular events.
- RPRX(Royalty Pharma): Its royalty interest in Amgen’s olpasiran now faces heightened risk after the pelacarsen failure triggered a class-wide reassessment. Discount the royalty asset until olpasiran demonstrates clinical-outcome benefit.
- CRWV(CoreWeave): Debt above $51 billion, bond yields above 17%, and permitting risks expose the company to acute refinancing and project-delivery pressure. Avoid or underweight until funding access and capacity execution stabilize.